MARKET

KLRS

KLRS

Kalaris Therapeutics Inc
NASDAQ
3.985
+0.015
+0.38%
Opening 15:13 08/12 EDT
OPEN
4.070
PREV CLOSE
3.970
HIGH
4.180
LOW
3.936
VOLUME
55.09K
TURNOVER
--
52 WEEK HIGH
11.88
52 WEEK LOW
2.140
MARKET CAP
94.81M
P/E (TTM)
-1.7996
1D
5D
1M
3M
1Y
5Y
1D
Analysts Offer Insights on Healthcare Companies: Airsculpt Technologies (AIRS), Biohaven Ltd. (BHVN) and Kalaris Therapeutics (KLRS)
TipRanks · 7h ago
Analysts Offer Insights on Healthcare Companies: Kodiak Sciences (KOD) and Kalaris Therapeutics (KLRS)
TipRanks · 22h ago
Analysts Offer Insights on Healthcare Companies: Mereo Biopharma Group Plc (MREO) and Kalaris Therapeutics (KLRS)
TipRanks · 1d ago
Kalaris Therapeutics GAAP EPS of -$0.48 in-line
Seeking Alpha · 1d ago
Weekly Report: what happened at KLRS last week (0803-0807)?
Weekly Report · 2d ago
Weekly Report: what happened at KLRS last week (0727-0731)?
Weekly Report · 08/03 10:22
Weekly Report: what happened at KLRS last week (0720-0724)?
Weekly Report · 07/27 10:26
Kalaris Therapeutics Strengthens Financial Leadership With New CFO
TipRanks · 07/20 12:29
More
About KLRS
Kalaris Therapeutics, Inc., formerly AlloVir, Inc., is a clinical-stage biopharmaceutical company engaged in the development and commercialization of treatments for prevalent retinal diseases. The Company is focused on the development of TH103, a differentiated anti-vascular endothelial growth factor (VEGF) investigational therapy. TH103 is a fully humanized, recombinant fusion protein that acts against VEGF as a decoy receptor and has been specifically engineered for potentially improved VEGF inhibition and longer retention in the retina. TH103 is being evaluated in an ongoing, Phase I clinical trial for the treatment of neovascular age-related macular degeneration (nAMD), with plans to develop TH103 for additional neovascular and exudative diseases of the retina such as diabetic macular edema (DME), and retinal vein occlusion (RVO).

Webull offers Kalaris Therapeutics Inc stock information, including NASDAQ: KLRS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KLRS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading KLRS stock methods without spending real money on the virtual paper trading platform.